CGEM has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CGEM has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
Cullinan Therapeutics's Sloan Ratio for the quarter that ended in Mar. 2024 was -9.88%.
As of Mar. 2024, Cullinan Therapeutics has a Sloan Ratio of -9.88%, indicating the company is in the safe zone and there is no funny business with accruals.
The historical data trend for Cullinan Therapeutics's Sloan Ratio % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cullinan Therapeutics Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Sloan Ratio % | Get a 7-Day Free Trial | 35.48 | -7.73 | 71.28 | -1.98 | -11.30 |
Cullinan Therapeutics Quarterly Data | ||||||||||||||||||||
Dec18 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Sloan Ratio % | Get a 7-Day Free Trial | -1.62 | 15.11 | 5.91 | -11.30 | -9.88 |
For the Biotechnology subindustry, Cullinan Therapeutics's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Cullinan Therapeutics's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Cullinan Therapeutics's Sloan Ratio % falls into.
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Cullinan Therapeutics's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Sloan Ratio | = | (Net Income (A: Dec. 2023 ) | - | Cash Flow from Operations (A: Dec. 2023 ) |
- | Cash Flow from Investing (A: Dec. 2023 )) | / | Total Assets (A: Dec. 2023 ) | |
= | (-153.162 | - | -134.275 | |
- | 35.806) | / | 484.182 | |
= | -11.30% |
Cullinan Therapeutics's Sloan Ratio for the quarter that ended in Mar. 2024 is calculated as
Sloan Ratio | = | (Net Income (TTM) | - | Cash Flow from Operations (TTM)) |
- | Cash Flow from Investing (TTM)) | / | Total Assets (Q: Mar. 2024 ) | |
= | (-132.348 | - | -121.525 | |
- | 33.578) | / | 449.43 | |
= | -9.88% |
Cullinan Therapeutics's Net Income for the trailing twelve months (TTM) ended in Mar. 2024 was -32.214 (Jun. 2023 ) + -39.183 (Sep. 2023 ) + -23.803 (Dec. 2023 ) + -37.148 (Mar. 2024 ) = $-132.35 Mil. Cullinan Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2024 was -31.006 (Jun. 2023 ) + -34.141 (Sep. 2023 ) + -18.131 (Dec. 2023 ) + -38.247 (Mar. 2024 ) = $-121.53 Mil. Cullinan Therapeutics's Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 was 12.11 (Jun. 2023 ) + -42.958 (Sep. 2023 ) + 51.47 (Dec. 2023 ) + 12.956 (Mar. 2024 ) = $33.58 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cullinan Therapeutics (NAS:CGEM) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
According to How to Beat the Market with the Sloan Ratio:
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Mar. 2024, Cullinan Therapeutics has a Sloan Ratio of -9.88%, indicating the company is in the safe zone and there is no funny business with accruals.
Thank you for viewing the detailed overview of Cullinan Therapeutics's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.
Nadim Ahmed | director, officer: President and CEO | C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901 |
Jacquelyn L Sumer | officer: Chief Legal Officer | C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140 |
Jeffrey Alan Jones | officer: Chief Medical Officer | ONE MAIN STREET, SUITE 520, CAMBRIDGE MA 02142 |
Jennifer Michaelson | officer: See Remarks | C/O CULLINAN MANAGEMENT, INC., ONE MAIN STREET SUITE 520, CAMBRIDGE MA 02142 |
Jeffrey Trigilio | officer: Chief Financial Officer | C/O CULLINAN MANAGEMENT, INC., ONE MAIN STREET, SUTIE 520, CAMBRIDGE MA 02142 |
David P. Ryan | director | C/O CULLINAN ONCOLOGY, INC., ONE MAIN STREET, SUITE 520, CAMBRIDGE MA 02142 |
Vision Scs F2 | 10 percent owner | 74 GRAND RUE, LUXEMBURG N4 L-1660 |
Savill Corrine | officer: Acting Chief Business Officer | C/O CULLINAN ONCOLOGY, LLC, ONE MAIN STREET SUITE 520, CAMBRIDGE MA 02142 |
F2 Bioscience I 2017 Ltd | 10 percent owner | 8, RUE SAINT-LEGER, GENEVA V8 CH 1205 |
Biotechnology Value Fund L P | other: See Explanation of Responses | 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104 |
Anne-marie Martin | director | ONE MAIN STREET, SUITE 520, CAMBRIDGE MA 02142 |
Mark N Lampert | 10 percent owner | 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104 |
Biotechnology Value Trading Fund Os Lp | other: See Explanation of Responses | P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104 |
Bvf Partners Os Ltd. | other: See Explanation of Responses | P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104 |
Biotechnology Value Fund Ii Lp | other: See Explanation of Responses | 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104 |
From GuruFocus
By Marketwired • 07-31-2023
By Value_Insider Value_Insider • 12-02-2022
By Marketwired • 08-09-2023
By Stock market mentor Stock market mentor • 02-02-2023
By GlobeNewswire GlobeNewswire • 12-02-2022
By Marketwired • 11-03-2023
By GuruFocus Research • 05-26-2023
By PRNewswire • 08-03-2023
By sperokesalga sperokesalga • 04-26-2023
By Marketwired • 09-06-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.